Abstract: A method of separation and/or recovery of a precious metal from a solution containing said precious metal in ionic form, optionally in the presence of impurities, including the step of contacting a solution containing said precious metal in ionic form with a conducting polymer. The method is generally applicable to precious metals including platinum (Pt), palladium (Pd) and more particularly gold (Au). The ionic species may be anionic (for example [AuCl4]?) or cationic. The polymer may be for example, a polypyrrole or polythiophene, optionally doped and are preferably in a high surface area form eg. coated onto cloth or RVC or in self supporting colloidal form. The polymer may also contain species to give further functionality, eg magnetic or heat sensitive species.

Abstract: Compounds of Formula (I) wherein R1, R2, R3, R4, R5, R6, and X are as defined herein for Formula (IA) and Formula (IB), or a tautomer, prodrug, solvate, or salt thereof, pharmaceutical compositions containing such compounds, and methods of modulating the glucocorticoid receptor function and methods of treating disease-states or conditions mediated by the glucocorticoid receptor function or characterized by inflammatory, allergic, or proliferative processes in a patient using these compounds.

Abstract: A method of separation and/or recovery of a precious metal from a solution containing said precious metal in ionic form, optionally in the presence of impurities, including the step of contacting a solution containing said precious metal in ionic form with a conducting polymer. The method is generally applicable to precious metals including platinum (Pt), palladium (Pd) and more particularly gold (Au). The ionic species may be anionic (for example [AuCl.sub.4].sup.-) or cationic. The polymer may be for example, a polypyrrole or polythiophene, optionally doped and are preferably in a high surface area form eg. coated onto cloth or RVC or in self supporting colloidal form. The polymer may also contain species to give further functionality, eg magnetic or heat sensitive species.

Abstract: Disclosed are compounds of formula (I) Where Ar1, X, Y, Q, W, R3, R4, R5, R6 and Ry are defined herein. The compounds of the invention inhibit production of cytokines involved in inflammatory processes and are thus useful for treating diseases and pathological conditions involving inflammation such as chronic inflammatory disease. The compounds are also useful for treating diseases or conditions related to oncology and anticoagulant or fibrinolytic therapy. Also disclosed are processes for preparing these compounds and pharmaceutical compositions comprising these compounds.

Abstract: A control program for a supervisor processor in a video-on-demand system directs the supervisor processor to perform the steps of: a) transfer a group of video data packets, from an externally stored complete video into a memory for the supervisor processor; b) build in the supervisor processor's memory, a respective subgroup of internet protocol headers for each video data packet in the group; and c) construct, in the memory of a co-processor, a transmission control list which indicates how each video data packet in the group, and its respective subgroup of internet protocol headers, can be accessed from the supervisor processor's memory by the co-processor.

Abstract: A control program for a co-processor in a video-on-demand system directs the co-processor to perform the steps of: a) obtain a transmission control list, from an external source, which identifies a group of several video data packets and a respective subgroup of internet protocol headers for each video data packet in the group; b) partition into pieces, each video data packet and its respective subgroup of internet protocol headers as identified by the transmission control list; and, c) send the partitioned pieces, along with an additional header for each piece, to an output port during a series of spaced apart time intervals.

Abstract: A video-on-demand system is comprised of a supervisor processor and a co-processor which are intercoupled via a bus. The supervisor processor has a supervisor memory and the co-processor has a co-processor memory. A supervisor control program is in the supervisor memory, which includes—a) a means for transferring a group of video data packets from an externally stored complete video into the supervisor memory, b) a means for building in the supervisor memory, a respective subgroup of internet protocol headers for each video data packet in the group, and c) a means for constructing in the co-processor memory, a transmission control list which indicates how each video data packet in the group and its respective subgroup of internet protocol headers can be accessed from the supervisor memory.

Abstract: Data throughput rates are increased in an optical fiber communication system without requiring replacement of the existing optical fiber in a link. Channel throughput is increased by upgrading the components and circuitry in the head and terminal of an optical fiber communication system link. Aggregate throughput in a fiber optic link is increased beyond the range of conventional Wavelength Division Multiplexed (WDM) upgrades, while precluding the necessity of replacing existing fiber plants. The increase in system throughput is achieved by using advanced modulation techniques to encode greater amounts of data into the transmitted spectrum of a channel, thereby increasing the spectral efficiency of each channel. This novel method of increasing transmission capacity by upgrading the head and terminal of the system to achieve greater spectral efficiency and hence throughput, alleviates the need to replace existing fiber plants.

Abstract: The present invention discloses immunomodulating compositions. More particularly, the present invention discloses compositions comprising an immune-modulating agent and a lectin-interactive agent, which are useful for stimulating and prolonging host immune cell responses. The compositions of the present invention are particularly useful in the treatment and/or prophylaxis of a range of conditions including pathogenic infections, autoimmune diseases, transplant rejection, graft versus host disease, allergies, inflammatory disease, as well as cancers and tumours.

Abstract: Decreasing the average transmitted power in an optical fiber communication channel using multilevel amplitude modulation in conjunction with Pulse Position Modulation (PPM). This multilevel PPM method does not entail any tradeoff between decreased power per channel and channel bandwidth, enabling a lower average transmitted power compared to On/Off Keying (OOK) with no reduction in aggregate data rate. Therefore, multilevel PPM can be used in high-speed Dense Wavelength Division Multiplexed (DWDM) systems where the maximum number of channels is traditionally limited by nonlinear effects such as self-phase modulation (SPM), cross-phase modulation (XPM), four-wave mixing (FWM), stimulated Brillouin scattering (SBS), and stimulated Raman scattering (SRS). This modulation technique can enable an increased number of channels in DWDM systems, thereby increasing aggregate data rates within those systems.

Abstract: A low magnetic signature motor system (1) comprises a plurality of electric motors (2), a first shield (9) and a second shield (13). The electric motors are arranged with their associated magnetic moments (6, 7) forming a closed loop such that their net external magnetic field (5) is minimized The first shield comprises a material with a high electrical conductivity and substantially surrounds the electric motors such that the a.c. component of the magnetic field is reduced; and the second shield comprises a material with a high magnetic permeability and substantially surrounds the first shield such that the d.c. magnetic field is reduced.

Abstract: Disclosed are benzimidazolone compounds of formulas (I) & (II): wherein R1, R2, R3, R4, R5, X, L, m, n and t are defined herein. The compounds inhibit production of cytokines involved in inflammatory processes and are thus useful for treating diseases and pathological conditions involving inflammation such as chronic inflammatory disease.

Abstract: Disclosed are compounds of formula (I) Where Ar1, X, Y, Q, W, R3, R4, R5, R6 and Ry are defined herein. The compounds of the invention inhibit production of cytokines involved in inflammatory processes and are thus useful for treating diseases and pathological conditions involving inflammation such as chronic inflammatory disease. The compounds are also useful for treating diseases or conditions related to oncology and anticoagulant or fibrinolytic therapy. Also disclosed are processes for preparing these compounds and pharmaceutical compositions comprising these compounds.

Abstract: A method of separation and/or recovery of a precious metal from a solution containing said precious metal in ionic form, optionally in the presence of impurities, including the step of contacting a solution containing said precious metal in ionic form with a conducting polymer. The method is generally applicable to precious metals including platinum (Pt), palladium (Pd) and more particularly gold (Au). The ionic species may be anionic (for example [AuCl4]?) or cationic. The polymer may be for example, a polypyrrole or polythiophene, optionally doped and are preferably in a high surface area form eg. coated onto cloth or RVC or in self supporting colloidal form. The polymer may also contain species to give further functionality, eg magnetic or heat sensitive species.

Abstract: Disclosed are benzimidazolone compounds of formulas (I) & (II): 1

Abstract: Disclosed are compounds of formula (I) 1

Abstract: Compounds of Formula (I) 1

Abstract: A low magnetic signature motor system (1) comprises a plurality of electric motors (2), a first shield (9) and a second shield (13). The electric motors are arranged with their associated magnetic moments (6,7) forming a closed loop such that their net external magnetic field (5) is minimised The first shield comprises a material with a high electrical conductivity and substantially surrounds the electric motors such that the a.c. component of the magnetic field is reduced; and the second shield comprises a material with a high magnetic permeability and substantially surrounds the first shield such that the d.c. magnetic field is reduced.

Abstract: A method and apparatus to verify the authenticity of the recording is provided. An authentication code is calculated based on the contents of the recording and information describing the context of the recording. The authentication code provides assurance to a user of the recording that no elements of the recording have been altered. Recordings that are made for legal evidence purposes may include, but are not limited to audio and visual (image) information including motion pictures. Context information includes, but is not limited to date, time, longitude, latitude, camera or recorder serial number, camera orientation, camera optical parameters, and information about the recorder operator. When using such recordings for legal evidence, the authenticity of the recorded information is crucial, and also the authenticity of the parameters surrounding the recording is crucial.

Abstract: Disclosed are recombinant, synthetically and otherwise biologically produced novel proteins and polypeptides which are encoded by the DNA sequence for HSV-2 glycoprotein G (gG) or fragments of said gG sequence particularly by the unique sequence for gG or portions of said unique sequence. The unique sequence proteins and polypeptides are serologically active, can be produced easily and safely at low cost, are useful as diagnostic reagents for HSV-2 and as vaccines against HSV-2. Further disclosed are serological assays based on such unique sequence gG proteins and polypeptides that diagnose the presence of herpes simplex virus type 2 (HSV-2) specific antibodies and can differentiate between HSV-2 and herpes simplex virus type 1 (HSV-1) specific antibodies. Such assays are useful to diagnose genital infections, to detect for exposure to HSV-2 and to screen pregnant women to protect newborns from neonatal HSV-2 infection.